Search

Peter J Langecker

from Monte Sereno, CA
Age ~73
Get Report
Also known as:
Peter Dr Langecker, Peter T Langecker, Peter Lange
Phone and address:
17610 Via Sereno, Los Gatos, CA 95030
(408) 354-9661
Related to:
Tamera Lange, 73Tamara A Langecker, 75
Connected to:
Barry S Langefeld, 75Brett A Langefels, 57Sean L Langeheine, 56Susan Langeheine, 54Adam G Langehough, 41Heather C Langejans, 45Brittany A Langel, 37Carmen M Langel, 57Christopher Q Langeland, 48Derrick J Langeland, 45

Peter Langecker Phones & Addresses

  • 17610 Via Sereno, Monte Sereno, CA 95030 (408) 354-9661 (408) 354-4414
  • Los Gatos, CA
  • South Lake Tahoe, CA
  • Walnut Creek, CA
  • Sunnyvale, CA
  • Westfield, NJ
  • Palo Alto, CA
  • 17610 Via Sereno, Monte Sereno, CA 95030 (408) 655-9422

Work

Company: Los gatos pharmaceuticals Jun 2014 to Dec 2015 Position: Co-founder and board member

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Ludwig - Maximilians Universität München 1984 to 1988 Specialities: Philosophy

Skills

Pharmaceutical Industry • Drug Development • Biotechnology • Oncology • Clinical Development • Clinical Trials • Life Sciences • Cro • Biopharmaceuticals • Medicine • Gcp • Clinical Research • Regulatory Affairs • Fda • Drug Discovery • Medical Devices • Cro Management • Infectious Diseases • Good Clinical Practice • U.s. Food and Drug Administration

Emails

l***[email protected]

Industries

Biotechnology

Resumes

Resumes

Peter Langecker Photo 1

Board Member

View page
Location:
Los Gatos, CA
Industry:
Biotechnology
Work:
Los Gatos Pharmaceuticals Jun 2014 - Dec 2015
Co-Founder and Board Member
Clinipace Worldwide Jun 2014 - Dec 2015
Executive Medical Director, Global Oncology
Oxigene Jun 2009 - May 2014
Chief Executive Officer and Chief Development Officer
Durect Corporation May 2006 - Jun 2009
Chief Medical Officer
Ciba-Geigy/Novartis Schering-Plough/Merck Coulter Pharmaceuticals Sugen/Pfizer Intarcia Oxigene May 2006 - Jun 2009
Roles of Increasing Responsibility In Clinical Research and Development
Education:
Ludwig - Maximilians Universität München 1984 - 1988
Doctorates, Doctor of Philosophy, Philosophy Ludwig - Maximilians Universität München 1978 - 1984
Doctor of Medicine, Doctorates, Medicine
Skills:
Pharmaceutical Industry
Drug Development
Biotechnology
Oncology
Clinical Development
Clinical Trials
Life Sciences
Cro
Biopharmaceuticals
Medicine
Gcp
Clinical Research
Regulatory Affairs
Fda
Drug Discovery
Medical Devices
Cro Management
Infectious Diseases
Good Clinical Practice
U.s. Food and Drug Administration

Publications

Us Patents

3-Heteroarylidenyl-2-Indolinone Compounds For Modulating Protein Kinase Activity And For Use In Cancer Chemotherapy

View page
US Patent:
20030073837, Apr 17, 2003
Filed:
Dec 30, 1999
Appl. No.:
09/476232
Inventors:
PETER LANGECKER - MONTE SERENO CA, US
LAURA SHAWVER - SAN FRANCISCO CA, US
PENG CHO TANG - MORAGE CA, US
LI SUN - FOSTER CITY CA, US
International Classification:
C 07D 4 3/02
US Classification:
544/333000, 544/238000, 544/405000
Abstract:
The present invention relates to 3-heteroarylidenyl-2-indolinone compounds that modulate the enzymatic activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer. Furthermore, these compounds are expected to enhance the efficacy of other chemotherapeutic agents, in particular, fluorinated pyrimidines, in the treatment of cancer.

Method For Treating Diseases With Omega Interferon

View page
US Patent:
20030143197, Jul 31, 2003
Filed:
Nov 8, 2002
Appl. No.:
10/290790
Inventors:
S. Moran - Orinda CA, US
Peter Langecker - Monte Sereno CA, US
Dennis Blanchett - Danville CA, US
International Classification:
A61K038/21
A61K031/4172
A61K039/42
US Classification:
424/085200, 424/085400, 424/161100, 514/400000
Abstract:
A method of treating an immunologic, proliferative, or infectious disease in a warm-blooded animal is disclosed. The method comprises administering to the animal omega interferon (IFN) at a dosage and activity for the disease state treated sufficient to induce a therapeutic response in the animal, which dosage and activity for the disease state treated is higher than would be well-tolerated based on data for non-omega IFN's. The omega IFN is administered alone or in combination with a therapeutically effective amount of at least one adjunctive therapeutic agent. Also disclosed is an article of manufacture useful for treating an immunologic, proliferative, or infectious disease, which article comprises (1) omega IFN in a form suitable for administering a therapeutically effective amount of the omega IFN to the subject in order to induce the desired therapeutic response (2) instructions for administering the omega IFN as desired, that is higher than would be well-tolerated based on data for non-omega IFNs.

3-Heteroarylidenyl-2-Indolinone Compounds For Modulating Protein Kinase Activity And For Use In Cancer Chemotherapy

View page
US Patent:
20030191162, Oct 9, 2003
Filed:
Dec 2, 2002
Appl. No.:
10/307483
Inventors:
Peter Langecker - Monte Sereno CA, US
Laura Shawyer - San Francisco CA, US
Peng Tang - Moraga CA, US
Li Sun - Foster City CA, US
Alison Hannah - Sebastopol CA, US
David Kwok - San Francisco CA, US
Assignee:
Sugen Inc.
International Classification:
A61K031/429
A61K031/427
A61K031/422
A61K031/4245
A61K031/4196
A61K031/4178
A61K031/404
A61K031/416
US Classification:
514/363000, 514/364000, 514/378000, 514/365000, 514/372000, 514/383000, 514/406000, 514/397000, 514/414000
Abstract:
The present invention relates to 3-heteroarylidenyl-2-indolinone compounds that modulate the enzymatic activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer. Furthermore, these compounds are expected to enhance the efficacy of other chemotherapeutic agents, in particular, fluorinated pyrimidines, in the treatment of cancer.

Combination Therapy For The Treatment Of Estrogen-Sensitive Disease

View page
US Patent:
20050130945, Jun 16, 2005
Filed:
Nov 5, 2004
Appl. No.:
10/982533
Inventors:
Stanford Moran - Orinda CA, US
Peter Langecker - Monte Sereno CA, US
International Classification:
A61K031/138
A61K031/56
US Classification:
514171000, 514651000
Abstract:
The present invention provides methods which increase the effectiveness of combination drug therapies for treating estrogen-sensitive diseases, such as breast cancer, as well as novel combinations useful to treat such diseases.

Combination Therapy For The Treatment Of Estrogen-Sensitive Disease

View page
US Patent:
20050176691, Aug 11, 2005
Filed:
Nov 5, 2004
Appl. No.:
10/982697
Inventors:
Stanford Moran - Orinda CA, US
Peter Langecker - Monte Sereno CA, US
International Classification:
A61K031/56
A61K031/55
A61K031/445
A61K031/138
US Classification:
514171000, 514217040, 514319000, 514651000
Abstract:
The present invention provides methods which increase the effectiveness of combination drug therapies for treating estrogen-sensitive diseases, such as breast cancer, as well as novel combinations useful to treat such diseases.

Combination Therapy For The Treatment Of Estrogen-Sensitive Disease

View page
US Patent:
20050228053, Oct 13, 2005
Filed:
Jun 3, 2005
Appl. No.:
11/144915
Inventors:
Stanford Moran - Orinda CA, US
Peter Langecker - Monte Sereno CA, US
International Classification:
C12Q001/00
A61K031/137
US Classification:
514651000, 435004000
Abstract:
The present invention provides methods which increase the effectiveness of combination drug therapies for treating estrogen-sensitive diseases, such as breast cancer, as well as novel combinations useful to treat such diseases.

Combination Therapy For The Treatment Of Estrogen-Sensitive Drugs

View page
US Patent:
20050232862, Oct 20, 2005
Filed:
Jun 3, 2005
Appl. No.:
11/144932
Inventors:
S. Moran - Orinda CA, US
Peter Langecker - Monte Sereno CA, US
International Classification:
A61K049/00
A61K031/56
A61K031/138
US Classification:
424009100, 514170000, 514651000
Abstract:
The present invention provides methods which increase the effectiveness of combination drug therapies for treating estrogen-sensitive diseases, such as breast cancer, as well as novel combinations useful to treat such diseases.

Method For Treating Diseases With Omega Interferon

View page
US Patent:
20070248572, Oct 25, 2007
Filed:
Jun 7, 2007
Appl. No.:
11/811415
Inventors:
S. Moran - Orinda CA, US
Peter Langecker - Monte Sereno CA, US
Dennis Blanchett - Danville CA, US
International Classification:
A61K 38/21
A61P 31/12
US Classification:
424085400
Abstract:
A method of treating an immunologic, proliferative, or infectious disease in a warm-blooded animal is disclosed. The method comprises administering to the animal omega interferon (IFN) at a dosage and activity for the disease state treated sufficient to induce a therapeutic response in the animal, which dosage and activity for the disease state treated is higher than would be well-tolerated based on data for non-omega IFN's. The omega IFN is administered alone or In combination with a therapeutically effective amount of at least one adjunctive therapeutic agent. Also disclosed is an article of manufacture useful for treating an immunologic, proliferative, or infectious disease, which article comprises (1) omega IFN in a form suitable for administering a therapeutically effective amount of the omega IFN to the subject in order to induce the desired therapeutic response (2) instructions for administering the omega IFN as desired, that is higher than would be well-tolerated based on data for non-omega IFNs.
Control profile
Peter J Langecker from Monte Sereno, CA, age ~73 Get Report